- Home
- CLPT vs EDIT Comparison
CLPT vs EDIT Comparison
Compare CLPT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | EDIT |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.9M | 422.3M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CLPT | EDIT |
|---|---|---|
| Price | $8.40 | $2.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $21.50 | $6.10 |
| AVG Volume (30 Days) | 668.9K | ★ 2.1M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | $31,937,000.00 |
| Revenue This Year | $31.18 | N/A |
| Revenue Next Year | $15.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.78 | ★ 132.64 |
| 52 Week Low | $8.27 | $1.66 |
| 52 Week High | $19.63 | $3.94 |
Technical Indicators
Market Signals| Indicator | CLPT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 38.02 |
| Support Level | N/A | $1.74 |
| Resistance Level | $11.93 | $2.29 |
| Average True Range (ATR) | 0.81 | 0.23 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 5.14 | 1.73 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.